Leerink Swann Upgrades Myriad Genetics (MYGN) to Outperform; Growth Prospects Good, Risks Overdone

Article Stock Quotes (1) Comments (0)

Leerink Swann upgraded Myriad Genetics (NASDAQ: MYGN) from Market Perform to Outperform, price target range raised from $27-30 to $30-31.

Analyst, Dan Leonard, said, "Following recent due diligence, which included several calls with MEDACorp clinicians and reimbursement specialists, as well as literature review, we are upgrading MYGN’s stock to Outperform. Key to our investment thesis is a view that: 1) the overhangs related to MYGN’s reimbursement and IP risks are overdone, and 2) MYGN’s core BRACAnalysis and COLARIS product lines should continue to grow."

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $24.54 yesterday, with a 52 week range of $17.51-$27.00.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: BofA/Merrill Lynch Upgrades Adobe (ADBE) to Buy
• UPDATE: BofA/Merrill Lynch Downgrades Cliffs Natural Resources (CLF) to Underperform
• DaVita (DVA), Myriad (MYGN) Units Enter Biomarker Collaboration

Create E-mail Alert Related Categories

Upgrades

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?